Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
News & insights
Publications: 07 OCTOBER 2020
The Covid-19 pandemic may have changed the dynamics of debt markets, but financing remains readily available for companies in sectors that have proven resilient throughout the Covid-19 crisis.Read more
News: 18 SEPTEMBER 2020
We have advised Apax Partners and its portfolio company Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), on the acquisition of the…Read more
Publications: 29 JULY 2020
Setting the stage Since long, discussions in Belgium have been ongoing as to who needs to prove that a patient was sufficiently informed about his/her treatment and its potential complications. With…Read more
Publications: 08 JULY 2020
Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.Read more